Glenmede Trust’s Clovis Oncology, Inc. CLVS Stock Holding History

Glenmede Trust’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-861	Closed	-$12	–	3158
2019 Q2	$12	Hold	861	–	–	﹤0.01%	2301
2019 Q1	$21	Hold	861	–	–	﹤0.01%	2050
2018 Q4	$15	Buy	+861	New	+$17.6K	﹤0.01%	2119
2018 Q3	–	Sell	-1,080	Closed	-$49K	–	1897
2018 Q2	$49K	Buy	1,080 +1,045	+2,986%	+$50.8K	﹤0.01%	1455
2018 Q1	$2K	Hold	35	–	–	﹤0.01%	2623
2017 Q4	$2K	Buy	+35	New	+$2.45K	﹤0.01%	2623
2015 Q3	–	Sell	-565	Closed	-$49K	–	2858
2015 Q2	$49K	Buy	+565	New	+$48.4K	﹤0.01%	1637

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Glenmede Trust's CLVS Position: Q3 2019 in Review

Glenmede Trust sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 861 shares — an estimated $12 sold.

Glenmede Trust first reported a position in CLVS in Q2 2015 and held it in 7 quarters. The position peaked at $49K in Q2 2018. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Glenmede Trust reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Glenmede Trust sold 861 Clovis Oncology, Inc. shares in Q3 2019, an estimated $12.
Glenmede Trust first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 7 quarters.
Glenmede Trust's Clovis Oncology, Inc. position peaked at $49K in Q2 2018.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Glenmede Trust's 13F filing for Q3 2019, filed 14 Nov 2019.